Dirk Jaeger
Overview
Explore the profile of Dirk Jaeger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
3034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
2.
Schmache T, Fohgrub J, Klimova A, Laaber K, Drukewitz S, Merboth F, et al.
Mol Cancer
. 2024 Jan;
23(1):10.
PMID: 38200602
Background And Aims: This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx). Methods: Endoscopic biopsies of patients...
3.
Hamid R, Alaziz M, Mahal A, Ashton A, Halama N, Jaeger D, et al.
Cells
. 2023 Sep;
12(18).
PMID: 37759462
The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating...
4.
Koerber S, Rohrich M, Walkenbach L, Liermann J, Choyke P, Fink C, et al.
J Nucl Med
. 2023 Sep;
64(11):1712-1720.
PMID: 37678928
Since the development of fibroblast activation protein-targeted radiopharmaceuticals, Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of...
5.
Apostolidis L, Lang K, Sisic L, Busch E, Ahadova A, Wullenkord R, et al.
J Cancer Res Clin Oncol
. 2022 Apr;
149(4):1373-1382.
PMID: 35441345
Purpose: Perioperative systemic treatment has significantly improved the outcome in locally advanced esophagogastric cancer. However, still the majority of patients relapse and die. Data on the optimal treatment after relapse...
6.
Haag G, Springfeld C, Grun B, Apostolidis L, Zschabitz S, Dietrich M, et al.
Eur J Cancer
. 2022 Apr;
167:112-122.
PMID: 35427833
Background: PD-1/PD-L1 inhibitors do not show activity in mismatch repair proficient (MMRp) colorectal cancer. Inhibition of C-C motif chemokine receptor 5 (CCR5) leads to an antitumoral activation of macrophages, affecting...
7.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga J, Morelli E, et al.
Leukemia
. 2021 Sep;
35(12):3628.
PMID: 34489554
No abstract available.
8.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga J, Morelli E, et al.
Leukemia
. 2021 May;
35(12):3509-3525.
PMID: 34007044
Bone marrow (BM) angiogenesis significantly influences disease progression in multiple myeloma (MM) patients and correlates with adverse prognosis. The present study shows a statistically significant correlation of the AP-1 family...
9.
Koerber S, Boesch J, Kratochwil C, Schlampp I, Ristau J, Winter E, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33805971
Men diagnosed with aggressive prostate cancer are at high risk of local relapse or systemic progression after definitive treatment. Treatment intensification is highly needed for that patient cohort; however, no...
10.
Eichhorn F, Klotz L, Kriegsmann M, Bischoff H, Schneider M, Muley T, et al.
Lung Cancer
. 2021 Feb;
153:150-157.
PMID: 33529989
Objectives: A phase II trial investigating the therapeutic effect of neoadjuvant programmed cell death 1 (PD-1) inhibitor pembrolizumab (MK-3475, KEYTRUDA®) administered prior to surgery for the treatment of non-small cell...